News & Updates

Sustained smoking cessation is associated with progressive reduction in the risk of ischaemic stroke, with substantial risk reduction observed after prolonged abstinence, according to a retrospective study.

New drug applications approved by US FDA as of 16-31 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Modifiable vascular risk factors and a history of stroke are associated with an increased risk of late-onset epilepsy, according to a meta-analysis.

Researchers from the Chinese University of Hong Kong (CUHK) have resolved a long-standing debate in neuroscience on the neural origin of complex muscle coordination for voluntary movements. Their recent finding that the brain organizes individual muscles into functional "building blocks" (muscle synergies) to coordinate multiple muscle groups simultaneously, rather than by directing each muscle individually, offers transformative insights for paralysis rehabilitation and design of brain-machine interfaces (BMIs) in future

A transcranial ultrasound-based wearable patch device appears to increase rapid eye movement (REM) sleep duration by 4.6 percent while reducing latency by 24 percent, as shown in a study.

In the treatment of patients with Parkinson disease (PD), nicotinamide riboside does not appear to confer beneficial effects and is even associated with worse clinical outcomes compared with placebo, according to a phase III trial.

Type 2 diabetes (T2D) patients receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) concomitantly appear to be at lower risk of dementia compared with those receiving a GLP-1 RA or SGLT-2i monotherapy, according to a study.

Intracranial abscesses in paediatric patients, although rare, need intensive multidisciplinary care, suggests a study, noting significant heterogeneity in current treatment strategies.

Researchers from the Chinese University of Hong Kong (CUHK) have developed a novel molecule, BB56, which can potentially serve as a lead compound for the development of new drugs for neuroinflammatory disorders.